Core Points - The company announced the resignation of its General Manager, Lu Junqiang, due to work adjustments, effective immediately upon submission of his resignation [1][2] - Vice General Manager, Li Jinqiu, will temporarily assume the responsibilities of the General Manager until a new appointment is made by the board [1] - Lu Junqiang will continue to hold a position in a company controlled by the major shareholder and actual controller [1] Company Governance - Lu Junqiang held 0.10% of the company's shares through Weihai Hongyang Rui Information Technology Center (Limited Partnership) [2] - The company will follow legal procedures to complete the election of a new director and the appointment of a new General Manager in accordance with relevant laws and regulations [2] - The board expressed gratitude for Lu Junqiang's contributions to the company's development during his tenure [2]

（文章来源：证券日报） 证券日报网讯 11月19日晚间，威高骨科发布公告称，公司董事会于11月19日收到公司董事、总经理卢 均强先生递交的书面辞职申请。因工作调整原因，卢均强先生不再担任公司第三届董事会董事、总经理 职务，由副总经理李进取先生代行总经理职责，直至董事会选聘新任总经理。卢均强先生将继续在公司 控股股东、实际控制人控制的企业内任职。 ...

北京商报讯（记者 丁宁）11月19日晚间，威高骨科（688161）发布公告称，公司董事会于11 月19日收 到公司董事、总经理卢均强递交的书面辞职申请。因工作调整原因，卢均强不再担任公司第三届董事会 董事、总经理职务，由副总经理李进取代行总经理职责，直至董事会选聘新任总经理。卢均强将继续在 公司控股股东、实际控制人控制的企业内任职。 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-045 截至本公告披露日，卢均强先生通过威海弘阳瑞信息技术中心（有限合伙） 持有公司 0.10%的股份。卢均强先生辞去公司董事和高管职务后，将继续严格遵 守《上海证券交易所科创板股票上市规则》《上市公司股东减持股份管理暂行办 法》《上市公司董事和高级管理人员所持本公司股份及其变动管理规则》等规定 及其所作的相关承诺。 公司将根据《中华人民共和国公司法》《上海证券交易所科创板股票上市规 则》及《公司章程》等相关规定，按照法定程序尽快完成公司董事的选举及总经 理的选聘等相关工作。 卢均强先生在担任公司董事、总经理期间，恪尽职守、勤勉尽责，为公司规 范运作和长远发展发挥了重要作用，公司及公司董事会对卢均强先生任职期间为 公司发展做出的贡献表示衷心感谢。 特此公告。 山东威高骨科材料股份有限公司董事会 山东威高骨科材料股份有限公司 关于公司董事、总经理工作调整的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 山东威高骨科材料股份有限公司（以下简称"公司"）董事会 ...

Market Overview - The net outflow of main funds in the Shanghai and Shenzhen markets reached 40.955 billion yuan, with the Sci-Tech Innovation Board experiencing a net outflow of 5.791 billion yuan [1] - A total of 178 stocks saw net inflows, while 415 stocks experienced net outflows [1] Sci-Tech Innovation Board Performance - On the Sci-Tech Innovation Board, 93 stocks rose, while 496 stocks fell, with one stock, He Xin Instrument, hitting the daily limit down [1] - C Hengkun, listed for 5 days, had a significant drop of 2.44% [1] Fund Flow Analysis - Among the 178 stocks with net inflows, five stocks had inflows exceeding 100 million yuan, led by Yuanjie Technology with a net inflow of 316 million yuan [2] - Other notable inflows included Changguang Huaxin and Yingshi Innovation, with net inflows of 144 million yuan and 113 million yuan, respectively [2] Continuous Fund Flow - 46 stocks showed continuous net inflows for more than three trading days, with Weigao Orthopedics leading at 10 consecutive days of inflow [2] - Conversely, 202 stocks experienced continuous net outflows, with Zhixiang Jintai leading at 17 consecutive days of outflow [2] Top Fund Inflows - The top stocks by net inflow included: - Yuanjie Technology: 315.73 million yuan, 10.22% inflow rate, 3.56% increase [2] - Changguang Huaxin: 144.31 million yuan, 11.14% inflow rate, 2.00% increase [2] - Yingshi Innovation: 113.72 million yuan, 21.35% inflow rate, 4.26% increase [2] Notable Outflows - The stocks with the highest net outflows included: - SMIC: 800.2 million yuan, 1.42% decrease [1] - Baiwei Storage: 344 million yuan outflow [1] - Guodun Quantum: 263 million yuan outflow [1]

证券代码：688161 证券简称：威高骨科 公告编号：2025-044 山东威高骨科材料股份有限公司 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容的 真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次会议是否有被否决议案：无 一、会议召开和出席情况 （三）出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及其持有表决权数量的情 况： ■ （四）表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 1、议案名称：《关于公司拟聘请会计师事务所的议案》 本次股东会由董事会召集，采用现场投票和网络投票相结合的方式召开，会议由董事长陈敏女士主持， 本次会议的召集、召开方式符合《公司法》、《证券法》、《公司章程》的规定。 （五）公司董事和董事会秘书的出席情况 1、公司在任董事9人，出席9人； 2、董事会秘书林青女士出席会议； 3、公司高管、见证律师列席本次会议。 二、议案审议情况 （一）非累积投票议案 审议结果：通过 表决情况： ■ （二）涉及重大事项，应说明5%以下股东的表决情况 ■ （三）关于议案表决的 ...

证券代码：688161 证券简称：威高骨科 公告编号：2025-044 山东威高骨科材料股份有限公司 一、 会议召开和出席情况 （一） 股东会召开的时间：2025 年 11 月 17 日 （二） 股东会召开的地点：山东威高骨科材料股份有限公司会议室（威海市旅 游度假区香江街 26 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 61 | | --- | --- | | 普通股股东人数 | 61 | | 2、出席会议的股东所持有的表决权数量 | 336,465,061 | | 普通股股东所持有表决权数量 | 336,465,061 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 84.1162 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 84.1162 | （四） 表决方式是否符合《公司法》及公司章程的规定，股东会主持情况等。 2025年第二次临时股东会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容 ...

北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 2025 年第二次临时股东会的 北京市中伦（深圳）律师事务所 关于山东威高骨科材料股份有限公司 二〇二五年十一月 法律意见书 2025 年第二次临时股东会的 法律意见书 致：山东威高骨科材料股份有限公司 法律意见书 根据中国证监会发布的《上市公司股东会规则》（下称"《股东会规则》"） 的有关规定，北京市中伦（深圳）律师事务所（下称"本所"）接受山东威高骨 科材料股份有限公司（下称"公司"）的委托，指派律师出席公司 2025 年第二次 临时股东会（下称"本次股东会"），并就本次股东会的召集和召开程序、召集人 资格、出席和列席会议人员资格、表决程序及表决结果等事宜发表法律意见。 本所及经办律师依据《中华人民共和国证券法》《律师事务所从事证券法律 业务管理办法》和《律师事务所证券法律业务执业规则》等规定及本法律意见书 出具日以前已经发生或者存在的事实，严格履行了法定职责，遵循了勤勉尽责和 诚实信用原则，进行了充分的核查验证，保证本法律意见所认定的事实真实、准 确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性陈述或者 重大遗漏，并承担相应法 ...

Core Viewpoint - Weigao Orthopedics has shown a positive performance in terms of stock price and trading volume, with significant financing activities indicating strong investor interest [1][2]. Financing Activities - On November 14, Weigao Orthopedics experienced a stock price increase of 1.24%, with a trading volume of 71.93 million yuan. The financing buy-in amount for the day was 14.26 million yuan, while the financing repayment was 12.78 million yuan, resulting in a net financing buy of 1.47 million yuan [1]. - As of November 14, the total financing and securities lending balance for Weigao Orthopedics was 150 million yuan, with the financing balance at 149 million yuan, accounting for 1.20% of the circulating market value, which is above the 90th percentile level over the past year [1]. Shareholder Information - As of September 30, the number of shareholders for Weigao Orthopedics reached 10,700, an increase of 18.33% compared to the previous period. The average circulating shares per person decreased by 15.49% to 37,418 shares [2]. - The company has distributed a total of 575 million yuan in dividends since its A-share listing, with 367 million yuan distributed over the past three years [3]. Financial Performance - For the period from January to September 2025, Weigao Orthopedics reported a revenue of 1.106 billion yuan, reflecting a year-on-year growth of 2.12%. The net profit attributable to the parent company was 207 million yuan, showing a significant increase of 26.24% year-on-year [2]. Institutional Holdings - As of September 30, 2025, Hong Kong Central Clearing Limited was the seventh-largest circulating shareholder, holding 3.4373 million shares, an increase of 392,000 shares from the previous period. Additionally, Penghua Medical Technology Stock A entered as the tenth-largest circulating shareholder with 1.0961 million shares [3].

Investment Rating - The industry investment rating is maintained as "Outperform the Market" [2][57]. Core Insights - The orthopedic consumables sector has shown continuous improvement in performance during the first three quarters of 2025, with a positive trend in overseas expansion [3][10]. - The overall revenue of the orthopedic consumables sector increased by 17% year-on-year for Q1-Q3 2025, with net profit attributable to shareholders rising by 81% [5][10]. - The gross profit margin for the sector improved to 66% in Q1-Q3 2025, reflecting effective cost control and optimization [4][10]. - The trend of companies actively pursuing international markets is expected to become a significant growth driver [10][27]. Summary by Sections 1. Orthopedic Consumables Q3 2025 Report Analysis - The orthopedic consumables sector's revenue for Q1-Q3 2025 reached 49.18 billion, with a year-on-year growth of 17% [9]. - The gross profit margin for Q3 2025 was reported at 67%, an increase of 2.06 percentage points compared to the previous year [10]. - The net profit attributable to shareholders for Q3 2025 doubled year-on-year, indicating significant performance improvement [10]. 2. Segment Analysis - The joint business segment has seen stable growth due to the continuation of centralized procurement and an increase in both volume and price for leading companies [19][24]. - The spinal segment is experiencing a steady execution of centralized procurement, with leading domestic brands increasing their market share [25]. - The trend of domestic companies expanding overseas is gaining momentum, with a focus on product innovation and international development [27][29]. 3. Related Company Q3 Report Summary - Major companies in the sector, such as Dabo Medical, Weigao Orthopedics, and Spring Medical, have shown strong revenue growth and profitability improvements in Q3 2025 [12][41][45]. - Dabo Medical reported a revenue of 18.76 billion, up 22.69% year-on-year, with a net profit of 4.25 billion, reflecting a 77.03% increase [45]. - Spring Medical achieved a remarkable revenue growth of 109.5% in Q3 2025, turning a previous loss into a profit of 770.6 million [33].